Stockreport

Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, Filspari. [Read more]